Structural Basis for Simvastatin Competitive Antagonism of Complement Receptor 3

Area of Science:

• Immunology
• Structural Biology
• Pharmacology

Background:

• The complement system mediates innate immunity but contributes to inflammatory diseases.
• Complement receptor 3 (CR3) antagonists are sought for therapeutic use, but their structural basis is unknown.
• Understanding CR3-ligand interactions is crucial for developing targeted anti-inflammatory therapies.

Purpose of the Study:

• To determine the structural basis for small molecule antagonism of complement receptor 3 (CR3).
• To investigate the mechanism by which simvastatin interacts with the CR3 I domain.
• To explore the potential of simvastatin as a CR3 antagonist for anti-inflammatory applications.

Main Methods:

• X-ray crystallography was used to determine the structure of the human CR3 I domain in complex with simvastatin.
• Biochemical assays were employed to assess simvastatin's effect on CR3 binding to complement fragments (iC3b, C3d) and ICAM-1.
• Cellular adhesion assays were performed using K562 cells and primary human monocytes under static and force-applied conditions.

Main Results:

• Simvastatin binds to the metal ion-dependent adhesion site (MIDAS) of the active CR3 I domain, directly interacting with the chelated Mg(2+) ion.
• Simvastatin antagonizes CR3 binding to iC3b and C3d, but not ICAM-1, with binding kinetics differentiating antagonism.
• Simvastatin inhibits CR3-mediated cell adhesion in a dose-dependent manner, with enhanced efficacy under applied force.

Conclusions:

• Simvastatin targets the ligand-binding activated conformation of CR3, providing a structural basis for its anti-inflammatory effects.
• This mechanism is relevant as the activated CR3 conformation is prevalent in pro-inflammatory environments.
• The findings pave the way for designing novel CR3 antagonists and identifying new druggable targets based on ligand-binding kinetics.